Description
Description
Tablets 500 mg: Biconvex tablets, coated with a white film coat, oblong shape. On a cross section – white or white with a creamy or grayish tint.
Release form
coated tablets
Pharmacological action
Antifibrinolytic agent. Tranexamic acid specifically inhibits the activation of profibrinolysin (plasminogen) and its conversion to fibrinolysin (plasmin). It has local and systemic hemostatic effects in case of bleeding associated with increased fibrinolysis (platelet pathology, menorrhagia). Also, tranexamic acid, due to the suppression of the formation of kinins and other active peptides involved in allergic and inflammatory reactions, has anti-allergic and anti-inflammatory effects.
Indications
Bleeding or risk of bleeding in the background: increased local fibrinolysis (uterine, including on the background of von Willebrand s disease and other coagulopathies, nasal, gastrointestinal bleeding, hematuria, bleeding after prostatectomy, cervical conization for cancer, tooth extraction in patients with hemorrhagic diathesis), generalized fibrinolysis (malignant neoplasms of the pancreas and prostate gland, operations on the organs of the chest, postpartum hemorrhage, manual separation of the placenta, leukemia, liver disease). Bleeding during pregnancy. Hereditary angioedema, allergic diseases (eczema, allergic dermatitis, urticaria, drug and toxic rash). Inflammatory diseases (tonsillitis, pharyngitis, laryngitis, stomatitis, aphthae of the oral mucosa).
Contraindications
Hypersensitivity to the drug, subarachnoid hemorrhage. With caution With caution, the drug is prescribed for thrombosis (cerebral vascular thrombosis, myocardial infarction, thrombophlebitis) or a threat to their development, with thrombohemorrhagic complications (in combination with heparin and indirect anticoagulants), color vision impairment, hematuria from the upper urinary tract (obstruction with a blood clot is possible), renal failure (cumulation is possible).
Special instructions
Before and during treatment it is necessaryexamination of an optometrist for visual acuity, color perception, fundus condition. In animal studies, no teratogenic and embryotoxic effects were detected.
Composition
Dosage 500 mg, one tablet contains: Active substance
Tranexamic acid 500 mg.
Excipients (core)
Microcrystalline cellulose, hyprolose, sodium carboxymethyl starch, talc, colloidal silicon dioxide, calcium stearate.
Excipients (shell)
Hypromellose, titanium dioxide, talc, macrogol.
Side effects of
When taking the drug, nausea, vomiting, heartburn, diarrhea, rash, skin itching, decreased appetite, drowsiness, and dizziness may occur. Color disturbance may occur rarely – thrombosis, thromboembolism.
Drug interaction
When combined with use of hemostatic drugs and hemocoagulase, thrombosis can be activated.
Overdose
Overdose on drug has not been provided.
Storage conditions
At a temperature not exceeding 30 ° C. Keep out of reach of children.
Shelf life
3 years. Do not use after expiration date.
Deystvuyushtee substance
Traneksamovaya Chisloth
dosage form
tablets
Prescription
Prescription
Nursing mothers, Adults prescribed by a doctor, Pregnant women prescribed by a doctor, Children prescribed by a doctor
Obninsk CPA, Russia
